HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Autor: Carlo-Stella, Carmelo 1, Ansell, Stephen 2, Zinzani, Pier Luigi 3, Radford, John 4, Maddocks, Kami 5, Pinto, Antonio 6, Collins, Graham P. 7, Bachanova, Veronika 8, Bartlett, Nancy 9, Bence-Bruckler, Isabelle 10, Hamadani, Mehdi 11, Kline, Justin 12, Mayer, Jiri 13, Savage, Kerry J. 14, Advani, Ranjana 15, Calmi, Paolo 16, Casasnovas, René-Olivier 17, Feldman, Tatyana 18, Hess, Brian 19, Bastos-Oreiro, Mariana 20, Iyengar, Sunil 21, Eisen, Sandy 22, Negievich, Yanina 22, Wang, Luqiang 23, Wuerthner, Jens 22, Herrera, Alex F. 24
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S347-S347
Databáze: ScienceDirect
Externí odkaz: